Personalis (NASDAQ:PSNL) Stock Price Down 8.6% – Should You Sell?

08 Jan 2026, 18:25 by Kim Johansen · The Markets Daily

Personalis, Inc. (NASDAQ:PSNL – Get Free Report) shares were down 8.6% during trading on Thursday . The stock traded as low as $8.69 and last traded at $8.5420. Approximately 219,692 shares traded hands during trading, a decline of 77% from the average daily volume of 941,280 shares. The stock had previously closed at $9.35.

Wall Street Analysts Forecast Growth

PSNL has been the topic of several research reports. Lake Street Capital reissued a “buy” rating and issued a $11.00 price target on shares of Personalis in a research note on Wednesday, November 5th. Morgan Stanley raised their target price on Personalis from $9.00 to $11.00 and gave the stock an “equal weight” rating in a research note on Monday, December 1st. Guggenheim boosted their price target on shares of Personalis from $6.00 to $12.00 and gave the company a “buy” rating in a research report on Tuesday, November 11th. Weiss Ratings restated a “sell (d-)” rating on shares of Personalis in a research report on Wednesday, October 8th. Finally, Wall Street Zen lowered Personalis from a “hold” rating to a “sell” rating in a research report on Saturday, January 3rd. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Personalis has a consensus rating of “Moderate Buy” and a consensus target price of $10.57.

Get Our Latest Research Report on Personalis

Personalis Stock Down 12.1%

The stock has a fifty day moving average of $8.77 and a 200-day moving average of $7.24. The stock has a market capitalization of $729.94 million, a PE ratio of -9.39 and a beta of 1.96.

Personalis (NASDAQ:PSNL – Get Free Report) last announced its quarterly earnings data on Tuesday, November 4th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.28) by $0.04. Personalis had a negative return on equity of 38.25% and a negative net margin of 106.92%.The business had revenue of $14.50 million during the quarter, compared to analysts’ expectations of $13.31 million. Equities research analysts expect that Personalis, Inc. will post -1.4 EPS for the current year.

Insider Buying and Selling

In related news, CEO Christopher M. Hall sold 29,612 shares of the stock in a transaction on Monday, November 3rd. The stock was sold at an average price of $8.99, for a total value of $266,211.88. Following the transaction, the chief executive officer owned 148,486 shares of the company’s stock, valued at $1,334,889.14. This represents a 16.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CFO Aaron Tachibana sold 103,668 shares of the firm’s stock in a transaction on Tuesday, November 25th. The shares were sold at an average price of $10.78, for a total value of $1,117,541.04. Following the completion of the sale, the chief financial officer owned 164,458 shares in the company, valued at approximately $1,772,857.24. This represents a 38.66% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 3.80% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the business. Royal Bank of Canada raised its position in Personalis by 3.2% in the 1st quarter. Royal Bank of Canada now owns 78,341 shares of the company’s stock valued at $275,000 after purchasing an additional 2,395 shares during the last quarter. Howland Capital Management LLC increased its stake in Personalis by 0.9% in the second quarter. Howland Capital Management LLC now owns 285,308 shares of the company’s stock valued at $1,872,000 after purchasing an additional 2,500 shares during the period. Legal & General Group Plc purchased a new stake in shares of Personalis in the second quarter valued at about $30,000. Ameritas Investment Partners Inc. acquired a new stake in shares of Personalis during the second quarter worth about $34,000. Finally, BNP Paribas Financial Markets grew its holdings in shares of Personalis by 406.4% during the second quarter. BNP Paribas Financial Markets now owns 6,451 shares of the company’s stock worth $42,000 after buying an additional 5,177 shares during the last quarter. Hedge funds and other institutional investors own 61.91% of the company’s stock.

About Personalis

(Get Free Report)

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.